Lovenox and Bronchial secretion retention - a phase IV clinical study of FDA data

Summary:

Bronchial secretion retention is reported as a side effect among people who take Lovenox (enoxaparin sodium), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Protonix, and have Pulmonary hypertension.

The phase IV clinical study analyzes which people have Bronchial secretion retention when taking Lovenox. It is created by eHealthMe based on reports of 47,547 people who have side effects when taking Lovenox from the FDA, and is updated regularly.

What is Lovenox?

Lovenox has active ingredients of enoxaparin sodium. It is often used in deep venous thrombosis. eHealthMe is studying from 48,149 Lovenox users. Check the latest studies of Lovenox.

What is Bronchial secretion retention?

Bronchial secretion retention is found to be associated with 279 drugs and 309 conditions by eHealthMe. Check the latest studies of Bronchial secretion retention.

On Jul, 19, 2026

47,547 people reported to have side effects when taking Lovenox.
Among them, 11 people (0.02%) have Bronchial secretion retention.

Could Lovenox cause Bronchial secretion retention?

Among these 11 people:

How long have people been on Lovenox when they have Bronchial secretion retention? *

What is the gender of people who have Bronchial secretion retention when taking Lovenox? *

female: 45.45 %
male: 54.55 %

What is the age of people who have Bronchial secretion retention when taking Lovenox? *

What are other drugs people take besides Lovenox? *

What are other side effects people have besides Bronchial secretion retention? *

Weakness: 8 people, 72.73%
Pneumonia: 7 people, 63.64%
Dyspnea (difficult or laboured breathing): 6 people, 54.55%
Acute Respiratory Failure: 5 people, 45.45%
Anaemia (lack of blood): 5 people, 45.45%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 5 people, 45.45%
Disease Progression: 5 people, 45.45%
Cough: 5 people, 45.45%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 5 people, 45.45%
Chest Pain: 5 people, 45.45%

What are the existing conditions these people have? *

Pulmonary Hypertension (increase in blood pressure in the lung artery): 5 people, 45.45%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 4 people, 36.36%
Sciatica (a set of symptoms including pain caused by general compression or irritation of one of five spinal nerve roots of each sciatic nerve): 1 person, 9.09%
Phlebitis Superficial (inflammation of the walls of a vein-superficial): 1 person, 9.09%
Confusional State: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Lovenox and have Bronchial secretion retention?

- Check whether Bronchial secretion retention is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lovenox:

Lovenox (48,149 reports)

Browse all side effects of Lovenox:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bronchial secretion retention:

Bronchial secretion retention (279 drugs)

Browse all the conditions that are associated with Bronchial secretion retention:

Bronchial secretion retention (309 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on enoxaparin sodium (the active ingredients of Lovenox) and Lovenox (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.